Key result
Established statin therapy prior to hospital admission was associated with a significantly reduced risk of 30-day mortality in patients hospitalized with community-acquired pneumonia (adjusted OR 0.58).
Why the study?
Does established statin therapy reduce 30-day mortality in patients hospitalized with community-acquired pneumonia?
Meta-Analysis (n=87,909)
Does established statin therapy reduce 30-day mortality in patients hospitalized with community-acquired pneumonia?
Established statin therapy is associated with a significant reduction in 30-day mortality among patients hospitalized with community-acquired pneumonia.
May support statin continuation in CAP; hypothesis-generating pending randomized confirmation.
Background: Statin therapy (ST) has been associated with improved outcomes from sepsis. Our objective was to systematically review the association between established ST and outcomes of patients with community-acquired pneumonia (CAP) that is severe enough to require hospitalisation. Methods: Two meta-analyses were conducted following a search of articles published before 31st January 2013. After exclusions, seven studies were included to assess the effects of statins on 30-day mortality from CAP, and eight studies were included to assess the effects of statins on the development of CAP. Endpoints were a reduction in the risk of 30-day mortality or risk of developing CAP. Results: A reduction in the risk of 30-day mortality from CAP was identified in patients established on ST (pooled odds ratio [OR]: 0.70, 95% confidence interval [CI]: 0.65-0.76; adjusted OR: 0.58, 95% CI: 0.47-0.69). The pooled OR for risk of developing CAP in patients with and without established ST was 1.01 (95% CI: 0.98-1.04). Conclusion: There appears to be weak evidence to suggest a potential benefit of established ST. It is associated with a reduced risk of 30-day mortality in patients subsequently hospitalised with CAP. Further evidence is required, but ST could be considered as a means of reducing the risk of mortality from pneumonia.
No takes yet. Share an insight, caveat, or question.
Fitzgerald et al. (2015) conducted a meta-analysis in Community-acquired pneumonia (n=87,909). Established statin therapy vs. No established statin therapy was evaluated on 30-day mortality (adjusted OR 0.58, 95% CI 0.47-0.69). Established statin therapy prior to hospital admission was associated with a significantly reduced risk of 30-day mortality in patients hospitalized with community-acquired pneumonia (adjusted OR 0.58).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: